OM:SOBIBiotechs
How Sobi’s Clinical Trial Results and FDA Approvals at ACR 2025 Will Impact (OM:SOBI) Investors
In October 2025, Swedish Orphan Biovitrum (Sobi) presented 15 scientific abstracts, including late-stage clinical trial results for Nanoencapsulated Sirolimus plus Pegadricase, Vonjo, and Gamifant, at the American College of Rheumatology (ACR) Convergence meeting in Chicago, with updates on both new safety data and recent US FDA approvals.
The company highlighted its strengthened leadership in rare and underserved inflammatory conditions, with the presentation of advanced clinical data and...